Payment overview · 2025
General Payments
$563.33
30 reported records · 10 companies
Healthcare provider profile · identity verified
Jon W Slotoroff, DO
Allopathic & Osteopathic Physicians|Internal Medicine · PLEASANTVILLE, NJ · NPI 1760565071
Verified facts
What the public records show
CMS Open Payments records show Jon W Slotoroff, DO received $563.33 in general payments during 2025 across 30 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $228.87 | 40.6% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $103.09 | 18.3% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $87.93 | 15.6% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $34.32 | 6.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.45 | 4.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.38 | 3.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.51 | 3.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.34 | 2.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.11 | 2.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.33 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $563.33 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $149.71 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $103.09 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $96.99 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $87.93 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $87.93 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $66.41 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $47.97 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $34.32 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.45 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $15.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 34 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 93 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 120 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
93 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
93 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
120 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 528 | 149 |
| Amlodipine Besylate | Amlodipine Besylate | 390 | 109 |
| Alprazolam | Alprazolam | 284 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 249 | 68 |
| Metformin Hcl | Metformin Hcl | 248 | 66 |
| Lisinopril | Lisinopril | 229 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 206 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 192 | 56 |
| Losartan Potassium | Losartan Potassium | 183 | 51 |
| Omeprazole | Omeprazole | 171 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 45 |
| Lorazepam | Lorazepam | 157 | 39 |
| Furosemide | Furosemide | 154 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 39 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 127 | 19 |
| Tramadol Hcl | Tramadol Hcl | 126 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 125 | 37 |
| Glimepiride | Glimepiride | 122 | 31 |
| Ozempic | Semaglutide | 120 | 23 |
| Carvedilol | Carvedilol | 117 | 34 |
| Gabapentin | Gabapentin | 115 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 30 |
| Atenolol | Atenolol | 101 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 96 | 14 |
| Jardiance | Empagliflozin | 93 | 17 |
| Allopurinol | Allopurinol | 90 | 26 |
| Celecoxib | Celecoxib | 90 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 24 |
| Metformin Hcl Er | Metformin Hcl | 79 | 25 |
| Clonidine Hcl | Clonidine Hcl | 78 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 23 |
| Eliquis | Apixaban | 76 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 68 | 16 |
| Prednisone | Prednisone | 66 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 19 |
| Bupropion Xl | Bupropion Hcl | 63 | 16 |
| Ibuprofen | Ibuprofen | 63 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 16 |
| Potassium Chloride | Potassium Chloride | 57 | 16 |
| Glipizide | Glipizide | 54 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 19 |
| Xarelto | Rivaroxaban | 51 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 47 | 17 |
| Simvastatin | Simvastatin | 47 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 12 |
| Sertraline Hcl | Sertraline Hcl | 44 | 14 |
| Clonazepam | Clonazepam | 43 | suppressed |
| Famotidine | Famotidine | 42 | 13 |
| Glipizide Er | Glipizide | 41 | 12 |
| Valsartan | Valsartan | 41 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 39 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Finasteride | Finasteride | 37 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 37 | 20 |
| Naproxen | Naproxen | 36 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 31 |
| Ezetimibe | Ezetimibe | 33 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Invokana | Canagliflozin | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 14 |
| Sucralfate | Sucralfate | 24 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 14 |
| Irbesartan | Irbesartan | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 11 |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 11 |
| Methylprednisolone | Methylprednisolone | 14 | 14 |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $563.33 · 30 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, FARXIGA, JARDIANCE, Kerendia, MOUNJARO, Ozempic, REXULTI, Repatha, Rybelsus, Veozah, XIFAXAN, ZEPBOUND, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error